Literature DB >> 18464119

Aberrant pre-mRNA splicing of a highly conserved cell cycle regulator, CDC25C, in myelodysplastic syndromes.

Jonathan S Caudill1, Julie C Porcher, David P Steensma.   

Abstract

Alternative pre-mRNA splicing alters gene expression and protein function, and aberrant splicing patterns can be associated with neoplasia. The potential role of disordered RNA splicing in myelodysplastic syndrome (MDS) is unexplored. We analysed the splicing repertoire of CDC25C- a gene localised to chromosome 5q31 and encoding a cyclin/cyclin-dependent-kinase regulatory phosphatase critical for cell cycle checkpoint control - in MDS, acute myeloid leukemia, chronic lymphocytic leukemia and healthy tissues. Five novel splicing isoforms were detected, and the splicing patterns were generally distinct in neoplastic samples compared with healthy controls. One of the novel isoforms, which we have termed CDC25C-6, occurred in 58% of the samples in our cohort. The results of this study suggest the possibility of aberrant splicing contributing to the phenotype in MDS and other haematologic malignancies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18464119     DOI: 10.1080/10428190801971690

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

Review 1.  Molecular pathophysiology of myelodysplastic syndromes.

Authors:  R Coleman Lindsley; Benjamin L Ebert
Journal:  Annu Rev Pathol       Date:  2012-08-28       Impact factor: 23.472

2.  CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.

Authors:  Sarah Bertoli; Helena Boutzen; Laure David; Clément Larrue; François Vergez; Anne Fernandez-Vidal; Lingli Yuan; Marie-Anne Hospital; Jérôme Tamburini; Cécile Demur; Eric Delabesse; Estelle Saland; Jean-Emmanuel Sarry; Marie-Odile Galcera; Véronique Mansat-De Mas; Christine Didier; Christine Dozier; Christian Récher; Stéphane Manenti
Journal:  Oncotarget       Date:  2015-11-10

3.  Myelodysplasia-associated mutations in serine/arginine-rich splicing factor SRSF2 lead to alternative splicing of CDC25C.

Authors:  Lindsey Skrdlant; Jeremy M Stark; Ren-Jang Lin
Journal:  BMC Mol Biol       Date:  2016-08-23       Impact factor: 2.946

4.  The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome.

Authors:  Yi-Tsung Yang; Yu-Chiao Chiu; Chein-Jun Kao; Hsin-An Hou; Chien-Chin Lin; Cheng-Hong Tsai; Mei-Hsuan Tseng; Wen-Chien Chou; Hwei-Fang Tien
Journal:  Blood Cancer J       Date:  2018-08-13       Impact factor: 11.037

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.